This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1538574408328586v1 1538574408328586v2 43/2/132    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by O'Donnell, M. E. Articles by Soong, C. Search for Related Content PubMed PubMed Citation Articles by O'Donnell, M. E. Articles by Soong, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB OXYGEN Medline Plus Health Information Peripheral Arterial Disease Social Bookmarking                         What's this?

The Vascular and Biochemical Effects of Cilostazol in Diabetic Patients With Peripheral Arterial Disease

Belfast City Hospital

^* To whom correspondence should be addressed. E-mail: modonnell904{at}hotmail.com.

	Abstract

Objectives: Cilostazol improves walking in patients with peripheral arterial disease (PAD). We hypothesized that cilostazol reduces diabetic complications in PAD patients.

Methods: Diabetic PAD patients were prospectively recruited to a randomized double-blinded, placebo-controlled trial, using cilostazol 100mg twice a day. Clinical assessment included ankle-brachial index, arterial compliance, peripheral transcutaneous oxygenation, treadmill walking distance and validated quality of life (QoL) questionnaires. Biochemical analyses included glucose and lipid profiles. All tests were at baseline, 6, and 24 weeks.

Results: 26 diabetic PAD patients (20 men) were recruited. Cilostazol improved absolute walking distance at 6 and 24 weeks (86.4% vs. 14.1%, P = .049; 143% vs. 23.2%, P = .086). Arterial compliance and lipid profiles improved as did some QoL indices for cilostazol at 6 and 24 weeks. Blood indices were similar at baseline and at follow-up points for both treatment groups.

Conclusions: Cilostazol is a well-tolerated and efficacious treatment, which improves claudication distances in diabetic PAD patients with further benefits in arterial compliance, lipid profiles, and QoL.

First published on January 8, 2009, doi:10.1177/1538574408328586

Vascular and Endovascular Surgery 2009;43:132.

A more recent version of this article appeared on April 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?